[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614202":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":36,"responsibleParty":56,"collaborators":20,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":20,"enrollmentInfo":68,"targetDuration":20,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":20,"overallStatus":39,"whyStopped":20,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"GI Windows, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Flexagon SFM plus OTOLoc for Magnet Colon Anastomosis","EXPERIMENTAL","Patients will receive the Flexagon Self Forming Magnet Anastomosis Plus OTOLoc for Creating side-to-side Ileo-colic, Colo-colonic and side-to-side or end-to-side Colorectal Anastomoses in Patients Undergoing Surgical Procedures via endoscopic or laparoscopic delivery methods",[13],"Device: Flexagon Self Forming Magnet Anastomosis Plus OTOLoc for Creating side-to-side Colon Anatomoses",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Flexagon Self Forming Magnet Anastomosis Plus OTOLoc for Creating side-to-side Colon Anatomoses","The SFM plus OTOLoc is used to create an immediate flow compression anastomosis for patients undergoing: Right or Left Hemicolectomy, Sigmoidectomy and Low Anterior resection",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Erik Wilson, MD","Chief Medical Officer","STUDY_CHAIR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Peter J Lukin, BS","CONTACT","9787610183","peter.lukin@giwindows.com",{"name":33,"role":29,"phone":34,"phoneExt":20,"email":35},"Jessica Musiak, BS","617-501-7697","jessica.musiak@giwindows.com",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Orlando Health","RECRUITING","Orlando","Florida","32806","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-81.37924,28.53834,{"lat":49,"lon":48},[52],{"name":53,"role":29,"phone":54,"phoneExt":20,"email":55},"Antonio Caycedo, MD., MSc","407-422-3790","antonio.caycedo@orlandohealth.com",{"type":57,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100614202","initial-safety-of-sfm-plus-otoloc-for-creating-side-to-side-or-end-to-side-colorectal-anastomoses-100614202",false,"NCT07276529","Initial Safety of SFM Plus OTOLoc for Creating Side-to-side or End-to-side Colorectal Anastomoses","Safety and Device Functionality of the Flexagon Self Forming Magnet Anastomosis Plus OTOLoc for Creating Ileo-colic, Colo-colonic and Colorectal Anastomoses in Patients Undergoing Surgical Procedures","Colonic","Inclusion Criteria:\n\n1. Aged 22 years or older at screening\n2. Candidate for surgery requiring Right of Left Hemicolectomy or Sigmoidectomy or Low Anterior resection with cardiac\u002Fmedical clearance for surgery\n3. Able to understand and sign informed consent document\n4. American Society of Anesthesiologists (ASA) score \\\u003C IV at time of procedure\n5. All cancer patients must have completed chemotherapy ≥2 months prior to procedure\n6. Lives, and intends to remain, within a 150-mile radius of study center for the duration of the study\n7. Able to refrain from smoking during study follow-up period\n\nExclusion Criteria:\n\n1. Known or suspected allergy to silicone, nickel, titanium or Nitinol\n2. BMI \\> 55 kg\u002Fm2\n3. Uncontrolled diabetes (defined as HbA1c \\>10%)\n4. Congenital or acquired anomalies of the GI tract, including atresia or malrotation that would inhibit passing of SFM magnet\n5. Participants with an acute diagnosis of obstructed or perforated colon cancer at the time of the Screening Visit\n6. Any documented conditions for which endoscopy and\u002For laparoscopy would be contraindicated or history of previous failed endoscopy that may suggest difficulty during endoscopic delivery of magnets\n7. History of recurrent small bowel obstructions.\n8. Coagulation deficiency not normalized by medical treatment or platelet count \\\u003C50,000\u002FµL\n9. Known moderate to severe renal disease (eGFR \\\u003C 44 milliliters per minute per 1.73m2) or ongoing dialysis\n10. Hyperkalemia \u002F hypercoagulability or prior Venus Thromboembolism \u002F Pulmonary Embolism\n11. Immunocompromised (e.g., active treatment for malignancies, hematologic malignancy, on immunosuppressive therapy, moderate or severe primary immunodeficiency, advanced or untreated HIV, active treatment with high-dose corticosteroids (i.e., 20 or more mg of prednisone or equivalent per day when administered for 2 or more weeks prior to surgery) or other immunosuppressive or immunomodulatory agents\n12. Congestive heart failure with ejection fraction \\\u003C35% or clinically significant arrhythmia (any rhythm disturbances except sinus tachycardia, sinus bradycardia or a sinus rhythm with premature atrial or ventricular complexes)\n13. Decompensated chronic obstructive lung disease\n14. Active or suspected infection at the surgical site or a CDC Class 3\u002Fcontaminated or Class 4\u002Fdirty-infected surgical wound.\n15. Contraindication to general anesthesia\n16. Breast-feeding, pregnant, or planning on becoming pregnant during the follow-up period\n17. Currently participating or has participated in another clinical trial within the past 30 days and is receiving\u002Fhas received an investigational drug, device, or biologic agent\n18. Contraindication to general anesthesia\n19. Participant is not appropriate for inclusion in the clinical trial, per the medical opinion of the Principal Investigator","ALL","22 Years",{"count":69,"type":70},20,"ESTIMATED","INTERVENTIONAL",[73],"NA","The primary objective of this trial is to investigate the safety and effectiveness of the Flexagon 25mm SFM system plus OTOLoc when used to create a side-to-side Ileo-colic, Colo-colonic and side-to-side or end-to-side colorectal anastomoses in participants undergoing colon surgery. This will be evaluated via a composite safety\u002Feffectiveness endpoint of patient success defined as successful creation of the target anastomosis without placement procedure, device or target anastomosis related reoperation through 30 days.",[76,77],"Colorectal Cancer","Diverticular Diseases","2026-04-09",{"date":80,"type":81},"2026-04-13","ACTUAL",{"date":83,"type":81},"2026-04-01",{"date":85,"type":70},"2026-08",{"name":5,"class":6},1]